Document is current
Any future updates will be listed below
-
Authors
Correll, Christoph U.
Angelov, Angel S.
Miller, Andrew C.
Weiden, Peter J. https://orcid.org/0000-0001-5583-5871
Brannan, Stephen K.
-
Funding
Funding for this research was provided by:
Karuna Therapeutics
- License Information
-
More Information
Article History
Received: 8 September 2022
Accepted: 21 November 2022
First Online: 3 December 2022
Competing interests
: The sponsor was involved in the design and conduct of the study; collection, analysis, and interpretation of data; preparation, review, and approval of the manuscript; and the decision to submit the manuscript for publication. Dr. Correll has been a consultant and/or advisor to or has received honoraria from AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Boehringer-Ingelheim, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Janssen/Johnson & Johnson, Karuna Therapeutics, LB Pharma, Lundbeck, MedAvante-ProPhase, MedinCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Newron, Noven, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Seqirus, SK Life Science, Sunovion, Sun Pharma, Supernus, Takeda, Teva, and Viatris; provided expert testimony for Janssen and Otsuka; served on a Data Safety Monitoring Board for Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva; has received grant support from Janssen and Takeda; received royalties from UpToDate; and is a stock option holder of Cardio Diagnostics, Mindpax, and LB Pharma. Drs. Angelov, Miller, Weiden, and Brannan are employees of and hold equity in Karuna Therapeutics.
